BridgeBio Pharma gains as investors refocus on pipeline catalysts ahead of expected earnings

BridgeBio Pharma (BBIO) is up 3.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to renewed bullish positioning ahead of an expected late-April earnings update, with investors leaning into BridgeBio’s commercial ramp for Attruby and recent regulatory progress for BBP-418. With no single company announcement clearly driving trading today, this could also reflect momentum from prior weeks’ catalysts and upbeat sell-side commentary.

Details:

BridgeBio submitted a U.S. New Drug Application for BBP-418 in LGMD2I/R9 in late March, a meaningful de-risking step that can pull investor attention back to additional potential launches beyond Attruby.

Recent analyst commentary has highlighted steady prescription trends and expectations for continued U.S. revenue growth for Attruby, supporting the “commercial durability” narrative for the franchise.

Longer-term outcomes data from the ATTRibute-CM open-label extension were presented at a major cardiology meeting in late March, adding incremental confidence around efficacy and safety durability.

Trading interest may be increasing into the company’s next quarterly results window (dates shown by market calendars vary), which can drive short-term positioning and volatility.

Sources:

SEC, BridgeBio Investor Relations, Investing.com, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BBIO Insider Trading Activity

$BBIO insiders have traded $BBIO stock on the open market 99 times in the past 6 months. Of those trades, 0 have been purchases and 99 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:

NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 74 sales selling 564,220 shares for an estimated $40,118,112.
FRANK MCCORMICK has made 0 purchases and 6 sales selling 200,000 shares for an estimated $13,313,192.
ANDREW LO has made 0 purchases and 4 sales selling 95,599 shares for an estimated $6,319,662.
ANDREA ELLIS sold 64,921 shares for an estimated $4,211,301
RONALD J DANIELS sold 61,031 shares for an estimated $3,888,999
HANNAH VALANTINE has made 0 purchases and 2 sales selling 34,155 shares for an estimated $2,308,039.
THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 4 sales selling 30,534 shares for an estimated $2,141,551.
RANDAL W. SCOTT has made 0 purchases and 5 sales selling 20,000 shares for an estimated $1,421,021.
MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,510 shares for an estimated $186,418.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

$BBIO Hedge Fund Activity

We have seen 232 institutional investors add shares of $BBIO stock to their portfolio, and 194 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRICE T ROWE ASSOCIATES INC /MD/ added 2,261,181 shares (+144.2%) to their portfolio in Q4 2025, for an estimated $172,957,734
JANUS HENDERSON GROUP PLC added 2,259,378 shares (+25.8%) to their portfolio in Q4 2025, for an estimated $172,819,823
MACQUARIE GROUP LTD removed 1,933,096 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $147,862,513
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,602,036 shares (-78.0%) from their portfolio in Q4 2025, for an estimated $122,539,733
VIKING GLOBAL INVESTORS LP removed 1,583,915 shares (-9.9%) from their portfolio in Q4 2025, for an estimated $121,153,658
WELLINGTON MANAGEMENT GROUP LLP added 1,329,537 shares (+130.4%) to their portfolio in Q4 2025, for an estimated $101,696,285
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,051,679 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $80,442,926

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$BBIO Congressional Stock Trading

Members of Congress have traded $BBIO stock 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 3 purchases worth up to $45,000 on 03/19, 03/18, 03/03 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.

$BBIO Analyst Ratings

Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

William Blair issued a "Outperform" rating on 03/10/2026
Barclays issued a "Overweight" rating on 01/28/2026
Truist Securities issued a "Buy" rating on 01/08/2026
Morgan Stanley issued a "Overweight" rating on 01/06/2026
JP Morgan issued a "Overweight" rating on 11/07/2025
HC Wainwright & Co. issued a "Buy" rating on 11/03/2025
Goldman Sachs issued a "Buy" rating on 10/31/2025

To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.

$BBIO Price Targets

Multiple analysts have issued price targets for $BBIO recently. We have seen 17 analysts offer price targets for $BBIO in the last 6 months, with a median target of $98.0.

Here are some recent targets:

Raghuram Selvaraju from HC Wainwright & Co. set a target price of $100.0 on 04/27/2026
Luca Issi from RBC Capital set a target price of $100.0 on 04/09/2026
Salim Syed from Mizuho set a target price of $106.0 on 03/18/2026
Anupam Rama from JP Morgan set a target price of $94.0 on 03/10/2026
Cory Kasimov from Evercore ISI Group set a target price of $125.0 on 02/25/2026
Sean Laaman from Morgan Stanley set a target price of $98.0 on 02/25/2026
Danielle Brill from Truist Securities set a target price of $95.0 on 02/25/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.